ストックスクリーナーアプリを入手
9.53
0.21%
-0.02
前日終値:
$9.55
開ける：
$9.5
24時間の取引高:
750.35K
Relative Volume:
0.74
時価総額：
$818.57M
収益：
-
当期純損益:
$-43.16M
株価収益率:
-17.33
EPS:
-0.55
ネットキャッシュフロー:
$-29.31M
1週間 パフォーマンス:
-4.17%
1か月 パフォーマンス:
-14.68%
6か月 パフォーマンス:
+14.13%
1年 パフォーマンス:
+55.46%
1日の値動き範囲:
$9.42
$9.76
1週間の範囲:
$9.265
$10.03
52週間の値動き範囲:
$4.9301
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
名前
Anavex Life Sciences Corporation
セクター
電話
844-689-3939
住所
630 5TH AVENUE, NEW YORK
AVXL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
9.53 | 823.72M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-06 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-09-23 | 開始されました | BTIG Research | Buy |
| 2020-12-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-09-28 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-02-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 開始されました | Janney | Buy |
| 2018-05-16 | 再開されました | Maxim Group | Buy |
| 2018-03-08 | 開始されました | ROTH Capital | Buy |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-02-07 | 開始されました | Noble Financial | Buy |
| 2016-03-29 | 開始されました | FBR Capital | Outperform |
すべてを表示
Anavex Life Sciences Corporation (AVXL) 最新ニュース
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease - MarketScreener
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease - The Manila Times
Anavex Life Sciences Corp. Announces Positive Results for Blarcamesine in Preventing Cognitive Decline in Alzheimer's Disease Model - Quiver Quantitative
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows - Benzinga
Complete Prevention of Memory Loss: Anavex's Alzheimer's Drug Shows Breakthrough in Animal Study - Stock Titan
Anavex Life Sciences Corp. Attempts Reversal From Key Support2025 Short Interest & Trade Opportunity Analysis - newsimpact.co.kr
Can volume confirm reversal in Anavex Life Sciences Corp.Weekly Investment Report & Long-Term Safe Return Strategies - Newser
Why Anavex Life Sciences Corp. is moving todayJuly 2025 PreEarnings & Verified Technical Trade Signals - Newser
Visual analytics tools that track Anavex Life Sciences Corp. performanceEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - Newser
Real time social sentiment graph for Anavex Life Sciences Corp.Portfolio Performance Report & Daily Volume Surge Signals - Newser
Risk adjusted return profile for Anavex Life Sciences Corp. analyzedEarnings Recap Report & Smart Money Movement Tracker - Newser
Regression analysis insights on Anavex Life Sciences Corp. performanceMarket Volume Report & Detailed Earnings Play Strategies - Newser
Is Anavex Life Sciences Corp. a candidate for recovery playEarnings Recap Summary & Fast Entry High Yield Tips - Newser
What technical models suggest about Anavex Life Sciences Corp.’s comebackEarnings Trend Report & Expert Approved Momentum Ideas - Newser
What data driven models say about Anavex Life Sciences Corp.’s futureJuly 2025 Drop Watch & Daily Profit Focused Stock Screening - Newser
Fibonacci Retracement Aligns with Support in Anavex Life Sciences Corp.2025 Technical Patterns & Precise Buy Zone Tips - 선데이타임즈
Is Anavex Life Sciences Corp. Forming a Bottom Pattern2025 Market WrapUp & Free Daily Entry Point Trade Alerts - sundaytimes.kr
Chart overlay techniques for tracking Anavex Life Sciences Corp.Earnings Performance Report & Risk Controlled Stock Pick Alerts - Newser
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q3 2025 Earnings Call Transcript - MSN
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital - Defense World
LPL Financial LLC Boosts Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
PNC Financial Services Group Inc. Has $495,000 Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Amends Executive Employment Contracts - MSN
Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders - ACCESS Newswire
Anavex: As The EMA Decision Nears, Key Risks Outweigh The Hype (NASDAQ:AVXL) - Seeking Alpha
Anavex Life Sciences: Fiscal Q3 Earnings Snapshot - Greenwich Time
Context Therapeutics Inc. shares fall 1.47% premarket after Anavex Life Sciences reports fiscal 2025 third quarter results. - AInvest
Anavex Life Sciences Reports Q3 2025 Financial Results - TipRanks
Can a trend reversal in Anavex Life Sciences Corp. lead to recoveryChart Signals & High Accuracy Swing Trade Signals - Newser
Achieve Life Sciences, Inc. shares rise 2.42% after-hours following positive earnings report. - AInvest
Anavex Life Sciences shares fall 4.76% intraday after reporting a wider fiscal Q3 loss. - AInvest
Earnings call transcript: Anavex Life Sciences Q3 2025 sees R&D drop - Investing.com
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update - The Globe and Mail
Anavex Life Sciences Corp. Q3 Loss Increases, Misses Estimates - Nasdaq
Anavex Life Sciences Fiscal Q3 Loss Widens - MarketScreener
Anavex Life Sciences Corp. Reports Q3 Fiscal 2025 Financial Results and Webcast Announcement - Quiver Quantitative
Earnings Flash (AVXL) Anavex Life Sciences Posts Fiscal Q3 Net Loss $0.16 a Share, vs. FactSet Est of $0.14 Loss - MarketScreener
Anavex Reports Breakthrough: Oral Alzheimer's Drug Maintains Benefits After 4 Years as Cash Position Tops $100M - Stock Titan
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
How high can Anavex Life Sciences Corp. stock goRSI and MACD Signal Summary with Trends - Newser
Understanding Anavex Life Sciences Corp.’s price movementSmart Trade Mapping with Entry Details - Newser
Why Anavex Life Sciences Corp. stock attracts strong analyst attentionSwing Watchlist With Tight Stop Placement - Newser
Sector ETF performance correlation with Anavex Life Sciences Corp.Stock Entry Points Based on Technicals - Newser
Historical volatility pattern of Anavex Life Sciences Corp. visualizedEquity Portfolio Outlook and Performance Summary - Newser
Published on: 2025-08-10 02:07:10 - Newser
Can Anavex Life Sciences Corp. recover in the next quarterROI Focused Setup Screener With Exit Markers - Newser
How Resilient Is Anavex Life Sciences Corp. Stock During Economic DownturnsFree Risk Controlled Short Term Trade Plans - Newser
Is Anavex Life Sciences Corp. stock reversal real or fakeIntraday Price Forecast Using Volume Models - Newser
Will Anavex Life Sciences Corp. outperform the marketVolume Spike Detection for Early Breakouts - Newser
Anavex Life Sciences Corporation (AVXL) 財務データ
収益
当期純利益
現金流量
EPS
Anavex Life Sciences Corporation (AVXL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):